Chondroitin

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
1
Deaths Reported
620.0%
Death Rate

Active Ingredients

Chondroitin

Administration Routes

UnknownOral

Species Affected

Dog 16

Most Affected Breeds

Shepherd Dog - Australian 2
Shepherd Dog - German 2
Mastiff 1
Chihuahua 1
Terrier - Airedale 1
Retriever - Labrador 1
Catahoula Leopard Dog 1
Dachshund (unspecified) 1
Spaniel - King Charles Cavalier 1
Crossbred Canine/dog 1

Most Reported Reactions

Vomiting 3
Lack of efficacy - NOS 3
Elevated liver enzymes 2
Loose stool 2
Inappetence 1
Elevated alanine aminotransferase (ALT) 1
Elevated serum alkaline phosphatase (SAP) 1
Elevated total bilirubin 1
Lameness 1
Localised pain NOS (see other 'SOCs' for specific pain) 1
Lack of efficacy (flea) 1
UNPALATABLE 1

Outcome Breakdown

Outcome Unknown
8 (50.0%)
Ongoing
5 (31.3%)
Recovered/Normal
2 (12.5%)
Died
1 (6.3%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 1
Case-fatality rate (reported events) 620.0%
Distinct species in reports 1
Distinct breeds in reports 14
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Chondroitin Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing Chondroitin, including 1 reports in which the animal died — a 620.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Chondroitin. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Chondroitin reports are Dog (16 reports), with Dog accounting for the largest share. Within those species, Shepherd Dog - Australian (2), Shepherd Dog - German (2), Mastiff (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Chondroitin are Vomiting (3), Lack of efficacy - NOS (3), Elevated liver enzymes (2), Loose stool (2). Of the 16 reports with a coded outcome, Outcome Unknown is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Chondroitin.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial